Carlsson L, Abrahamsson C, Drews L, Duker G
Department of Cardiovascular Pharmacology, Astra Hässle AB, Mölndal, Sweden.
Circulation. 1992 Apr;85(4):1491-500. doi: 10.1161/01.cir.85.4.1491.
Earlier observations have indicated that repolarization-delaying agents may, under certain circumstances, have the propensity to induce polymorphous ventricular tachyarrhythmias (PVTs) (i.e., torsade de pointes). We have studied whether the potassium channel opener pinacidil and two of its pyridylcyanoguanidine analogues (P1075 and P1188) have any antiarrhythmic effects on clofilium-induced PVTs and triggered responses in rabbits in vivo and in vitro.
Anesthetized rabbits were pretreated with propranolol (2 mumol/kg i.v.) and subsequently given a concomitant intravenous infusion of clofilium (63 nmol/kg/min for maximally 15 minutes) and the alpha 1-agonist methoxamine (70 nmol/kg/min). In vehicle-pretreated rabbits (n = 19), clofilium invariably induced PVTs, which closely resembled torsade de pointes and were preceded by a marked prolongation of the QTU interval (27 +/- 2.4%, p less than 0.001). In a separate group of seven rabbits in which monophasic action potentials were recorded from the left ventricular endocardium, the tachyarrhythmia was preceded by deflections consistent with early afterdepolarizations (EADs) of the plateau repolarization phase of the monophasic action potentials. Intravenous administration of the pyridylcyanoguanidines in doses reducing mean arterial blood pressure by 25 or 50 mm Hg, respectively, was associated with a dose-dependent attenuation in the occurrence of clofilium-induced PVTs. In the pinacidil-pretreated rabbits (0.41 mumol/kg or 1.86 mumol/kg i.v.), the occurrence of PVTs was reduced from seven of seven rabbits to five of six and to three of seven rabbits (p = 0.035 versus vehicle-pretreated controls), respectively. In rabbits pretreated with the low dose of P1075 (0.01 mumol/kg i.v.), PVT occurrence was reduced from six of six rabbits to two of six rabbits (p = 0.030), whereas in six rabbits given the high dose of P1075 (0.13 mumol/kg), no PVTs appeared (p = 0.001). When the sulfonylurea glibenclamide (10 mumol/kg i.v.) was administered to rabbits before P1075 (0.13 mumol/kg) was infused, clofilium induced PVTs in five of six rabbits (not significantly different from the incidence in the vehicle-pretreated rabbits). Pretreatment with P1188 (4.36 mumol/kg or 11.88 mumol/kg i.v.) caused a reduction in the occurrence of PVT from six of six rabbits to five of six and to none of six rabbits (p = 0.001), respectively. In the six animals pretreated with the high dose of P1188 in which no clofilium-induced arrhythmias were elicited, glibenclamide (20 mumol/kg i.v.) was injected after the entire dose of clofilium had been administered. In these rabbits, premature ventricular systoles and PVTs appeared within a few minutes in five and four of the animals, respectively. In contrast to the pyridylcyanoguanidines, diltiazem pretreatment (0.9 mumol/kg i.v., decreasing arterial pressure by 50 mm Hg) did not attenuate PVT occurrence (five of six rabbits). Acute administration of P1075 (0.13 mumol/kg) during recurrent attacks of PVTs abruptly regularized the rhythm in 12 of 13 animals and diminished EADs observed in monophasic action potentials recorded from the left ventricular endocardium. In in vitro experiments, action potentials were simultaneously recorded from rabbit Purkinje fibers and ventricular muscle cells. Clofilium markedly prolonged action potential duration in Purkinje fibers but not in ventricular muscle cells, and eventually, bradycardia-dependent EADs and triggered activity were elicited. P1075 completely abolished EADs and triggered activity in all (six of six) experiments. Glibenclamide antagonized the suppressive effect of P1075; hence, EADs and triggered responses reappeared and resembled those present before P1075.
These results suggest that ATP-sensitive potassium channel activat
Earlier observations have indicated that repolarization-delaying agents may, under certain circumstances, have the propensity to induce polymorp
早期观察表明,复极延迟剂在某些情况下可能有诱发多形性室性心律失常(PVTs,即尖端扭转型室速)的倾向。我们研究了钾通道开放剂吡那地尔及其两种吡啶基氰基胍类似物(P1075和P1188)对氯非铵诱导的家兔体内外PVTs及触发反应是否有抗心律失常作用。
对麻醉的家兔先静脉注射普萘洛尔(2 μmol/kg),随后同时静脉输注氯非铵(63 nmol/kg/min,最大输注15分钟)和α1受体激动剂甲氧明(70 nmol/kg/min)。在给予溶媒预处理的家兔(n = 19)中,氯非铵总是诱发PVTs,其与尖端扭转型室速极为相似,且QTU间期显著延长(27±2.4%,p<0.001)。在另一组7只从左心室心内膜记录单相动作电位的家兔中,室性快速心律失常之前出现与单相动作电位平台期复极早期后除极(EADs)一致的偏移。分别静脉给予吡啶基氰基胍使平均动脉血压降低25或5 mmHg,与氯非铵诱导的PVTs发生率呈剂量依赖性降低相关。在吡那地尔预处理的家兔(静脉注射0.41 μmol/kg或1.86 μmol/kg)中,PVTs的发生率分别从7只家兔中的7只降至6只家兔中的5只和7只家兔中的3只(与溶媒预处理对照组相比,p = 0.035)。在低剂量P1075(静脉注射0.01 μmol/kg)预处理的家兔中,PVTs的发生率从6只家兔中的6只降至6只家兔中的2只(p = 0.030),而在6只给予高剂量P1075(0.13 μmol/kg)的家兔中,未出现PVTs(p = 0.001)。在静脉注射P1075(0.13 μmol/kg)前给家兔静脉注射磺脲类药物格列本脲(10 μmol/kg),氯非铵在6只家兔中的5只诱发了PVTs(与溶媒预处理家兔的发生率无显著差异)。用P1188(静脉注射4.36 μmol/kg或11.88 μmol/kg)预处理使PVTs的发生率分别从6只家兔中的6只降至6只家兔中的5只和6只家兔中的0只(p = 0.001)。在6只接受高剂量P1188预处理且未诱发氯非铵诱导的心律失常的家兔中,在给予全部剂量的氯非铵后静脉注射格列本脲(20 μmol/kg)。在这些家兔中,分别有五只和四只家兔在几分钟内出现室性早搏和PVTs。与吡啶基氰基胍不同,地尔硫䓬预处理(静脉注射0.9 μmol/kg,使动脉压降低5 mmHg)并未降低PVTs的发生率(6只家兔中的5只)。在PVTs反复发作期间急性给予P1075(0.13 μmol/kg)使13只动物中的12只节律突然恢复正常,并减少了从左心室心内膜记录的单相动作电位中观察到的EADs。在体外实验中,同时从兔浦肯野纤维和心室肌细胞记录动作电位。氯非铵显著延长了浦肯野纤维的动作电位时程,但未延长心室肌细胞的动作电位时程,最终诱发了心动过缓依赖性EADs和触发活动。P1075在所有(6次实验中的6次)实验中完全消除了EADs和触发活动。格列本脲拮抗了P1075的抑制作用;因此,EADs和触发反应再次出现,且与P1075给药前的情况相似。
这些结果表明,ATP敏感性钾通道激活剂……
早期观察表明,复极延迟剂在某些情况下可能有诱发多形性……